A Phase 2 interventional study of Placebo and MEDI9929 70 mg in Asthma, sponsored by MedImmune LLC. Completed at 107 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-12-04.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 4 in phase 2, and was the 2nd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2013.
This study's enrollment of 584 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 60th largest by enrollment of the 248 interventional ones that give a count, is one of 7 that started in 2013, is one of 50 in phase 2, and was the 181st registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Drug: Placebo
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Drug: MEDI9929 70 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Drug: MEDI9929 210 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Drug: MEDI9929 280 mg
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Annualized Asthma Exacerbation Rate (AER) Through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Time frame: Week 0 (Day 1) up to Week 52
Reduction in AER on Subpopulations at Week 52
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Reduction in AER was evaluated in pre-specified subpopulations (blood eosinophil count \[eosinophilic and non-eosinophilic\], T helper cell 2 \[Th2\] status \[high and low\], Fraction of exhaled nitric oxide \[FENO\] \[high and low\], serum periostin \[high and low\], current post bronchodilator forced expiratory volume in 1 second \[Post-BD FEV1\] reversibility- yes, allergic and non-allergic) of asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up. Also, the high or low was determined using median value.
Time frame: Week 52
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52
Forced expiratory volume in 1 second and forced vital capacity measures taken before bronchodilator use were reported.
Time frame: Baseline (Week 0 [Day 1]) to Week 52
Change From Baseline in FEV1 on Subpopulations at Week 52
Forced expiratory volume in one second (FEV1) was evaluated in pre-specified subpopulations of asthma. The data presented in the below table for this outcome measure is for pre-bronchodilator FEV1.
Time frame: Baseline and up to Week 52
Change From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52
Forced expiratory volume in 1 second and forced vital capacity measures taken after bronchodilator use were reported.
Time frame: Baseline (Week 0 [Day 1]) to Week 52
Change From Baseline in Overall Symptoms Score on Subpopulations at Week 52
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Overall symptom score is the average of scores of daytime severity, daytime frequency, and nighttime severity symptoms. The daytime frequency and severity items are scored from 0 to 4, where a higher score indicates greater frequency/severity and nighttime severity item is scored from 0 to 4 , where a higher score indicates greater severity. Overall symptom score ranges from 0 to 4, where lower score indicates better asthma symptom while, higher score indicates worse asthma symptom.
Time frame: Baseline and up to Week 52
Change From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Symptom score values for night time assessment is 0 (no asthma symptom) to 3 (unable to sleep because of asthma) and symptom score values for day time assessment is 0 (no asthma symptom) to 3 (unable to do normal activities due to asthma). Total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom.
Time frame: Baseline (Week 0 [Day 1]) and Week 52
Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52
The ACQ is a patient-reported questionnaire assessing asthma symptoms (ie, night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use and FEV1. The ACQ-6 is a shortened version of the ACQ that omits the FEV1 measurement from the original ACQ score. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).
Time frame: Baseline (Week 0 [Day 1]) and Week 52
Rate of Severe Asthma Exacerbation Through Week 52
A severe asthma exacerbation is defined as an event that resulted in hospitalization. The severe AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Time frame: Week 0 (Day 1) up to Week 52
Time to First Asthma Exacerbation Through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first asthma exacerbation was reported.
Time frame: Week 0 (Day 1) through Week 52
Time to First Severe Asthma Exacerbation Through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first severe asthma exacerbations (hospitalization) were reported.
Time frame: Week 0 (Day 1) through Week 52
Number of Participants With at Least One Asthma Exacerbations Through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
Time frame: Week 0 (Day 1) through Week 52
Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Participants with severe asthma exacerbations (hospitalization) were reported.
Time frame: Week 0 (Day 1) through Week 52
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52
The AQLQ(S) +12 is a 32-item questionnaire that measures the health-related quality of life experienced by asthma participants. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli) scaled on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment).
Time frame: Baseline (Week 0 [Day 1]) and Week 52
Change From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a visual analogue scale (VAS) that ranged from 0 to 100, where 0 indicated the worst health you can imagine and 100 indicated the best health you can imagine.
Time frame: Baseline (Week 0 [Day 1]) and Week 52
Total Amount of Study Drug Exposure
The total amount of study drug exposure (in milligram) for the entire study period was summarized.
Time frame: Week 0 (Day 1) through Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product. Serious adverse event is any adverse event that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period until and including the follow-up period (Week 64).
Time frame: Day 1 upto Week 64
Number of Participants With TEAEs Related to Vital Sign Parameters
Adverse events observed in participants with clinically significant vital signs abnormalities were assessed.
Time frame: Day 1 upto Week 64
Number of Participants With TEAEs Related to Clinical Laboratory Evaluation
An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations of blood and urine samples were performed.
Time frame: Day 1 upto Week 64
Number of Participants With TEAEs Related to Electrocardiogram Evaluations
Adverse events observed in participants with clinically significant electrocardiogram abnormalities were assessed.
Time frame: From the start of study drug administration upto Week 64
Mean Serum Concentrations of MEDI9929
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
Time frame: Week 0 (Day 1) to Week 64
Number of Participants With Positive Antibodies to MEDI9929
Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The number of participants with positive serum antibodies to MEDI9929 were presented.
Time frame: Week 0 (Day 1) to Week 64
The study was conducted from 19Dec2013 to 01Mar2017 across 12 countries (United States, Slovakia, Bulgaria, Czech Republic, Hungary, Israel, Japan, Latvia, Lithuania, Serbia, South Africa, and Ukraine). A total of 918 participants were recruited in the study.
| Milestone | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Started | 138 | 138 | 137 | 137 |
| Completed | 130 | 127 | 122 | 115 |
| Not completed | 8 | 11 | 15 | 22 |
| Withdrew: Withdrawal by subject | 4 | 4 | 7 | 10 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 |
| Withdrew: Missed dose | 4 | 6 | 7 | 10 |
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
| events per person-year | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Annualized Asthma Exacerbation Rate (AER) Through Week 52 | 0.72 (0.59 to 0.88) | 0.27 (0.19 to 0.38) | 0.20 (0.13 to 0.30) | 0.23 (0.16 to 0.34) |
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Reduction in AER was evaluated in pre-specified subpopulations (blood eosinophil count \[eosinophilic and non-eosinophilic\], T helper cell 2 \[Th2\] status \[high and low\], Fraction of exhaled nitric oxide \[FENO\] \[high and low\], serum periostin \[high and low\], current post bronchodilator forced expiratory volume in 1 second \[Post-BD FEV1\] reversibility- yes, allergic and non-allergic) of asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up. Also, the high or low was determined using median value.
| events per person-year | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Blood Eosinophil Count -Eosinophilic | 0.78 (0.59 to 1.00) | 0.29 (0.18 to 0.43) | 0.26 (0.16 to 0.42) | 0.21 (0.12 to 0.35) |
| Blood Eosinophil Count -Non-Eosinophilic | 0.65 (0.46 to 0.89) | 0.25 (0.14 to 0.42) | 0.14 (0.06 to 0.27) | 0.26 (0.14 to 0.43) |
| Th2 Status - High | 0.62 (0.45 to 0.83) | 0.33 (0.20 to 0.50) | 0.25 (0.14 to 0.41) | 0.21 (0.11 to 0.36) |
| Th2 Status - Low | 0.86 (0.64 to 1.13) | 0.23 (0.14 to 0.37) | 0.15 (0.07 to 0.28) | 0.26 (0.15 to 0.41) |
| FENO - High | 0.94 (0.72 to 1.20) | 0.32 (0.20 to 0.48) | 0.20 (0.11 to 0.35) | 0.20 (0.10 to 0.35) |
| FENO - Low | 0.51 (0.36 to 0.72) | 0.23 (0.13 to 0.38) | 0.21 (0.11 to 0.36) | 0.28 (0.16 to 0.44) |
| Serum Periostin - High | 0.78 (0.59 to 1.02) | 0.29 (0.17 to 0.45) | 0.19 (0.10 to 0.33) | 0.19 (0.10 to 0.32) |
| Serum Periostin - Low | 0.66 (0.48 to 0.89) | 0.27 (0.16 to 0.42) | 0.22 (0.12 to 0.38) | 0.30 (0.18 to 0.47) |
| Current Post-BD FEV1 Reversibility-Yes | 0.60 (0.47 to 0.75) | 0.26 (0.18 to 0.37) | 0.17 (0.10 to 0.27) | 0.21 (0.14 to 0.32) |
| Allergic | 0.75 (0.57 to 0.97) | 0.25 (0.15 to 0.40) | 0.14 (0.07 to 0.26) | 0.23 (0.13 to 0.38) |
| Non-Allergic | 0.65 (0.44 to 0.91) | 0.23 (0.12 to 0.39) | 0.26 (0.13 to 0.45) | 0.22 (0.11 to 0.38) |
Forced expiratory volume in 1 second and forced vital capacity measures taken before bronchodilator use were reported.
| Liter | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Change from Baseline in Pre-BD FEV1 | 0.071 ± 0.405 | 0.200 ± 0.432 | 0.210 ± 0.433 | 0.245 ± 0.411 |
| Change from Baseline in Pre-BD FVC | 0.068 ± 0.477 | 0.244 ± 0.560 | 0.202 ± 0.616 | 0.197 ± 0.484 |
Forced expiratory volume in one second (FEV1) was evaluated in pre-specified subpopulations of asthma. The data presented in the below table for this outcome measure is for pre-bronchodilator FEV1.
| Liters | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Blood Eosinophil Count -Eosinophilic | -0.045 ± 0.080 | 0.118 ± 0.083 | 0.125 ± 0.086 | 0.160 ± 0.080 |
| Blood Eosinophil Count -Non-Eosinophilic | -0.072 ± 0.105 | -0.030 ± 0.112 | 0.008 ± 0.106 | 0.011 ± 0.108 |
| Th2 Status - High | -0.058 ± 0.101 | 0.037 ± 0.109 | 0.052 ± 0.107 | 0.182 ± 0.104 |
| Th2 Status - Low | -0.052 ± 0.085 | 0.103 ± 0.086 | 0.103 ± 0.088 | 0.062 ± 0.086 |
| FENO - High | -0.054 ± 0.078 | 0.093 ± 0.084 | 0.137 ± 0.083 | 0.155 ± 0.079 |
| FENO - Low | 0.027 ± 0.074 | 0.115 ± 0.076 | 0.095 ± 0.073 | 0.133 ± 0.075 |
| Serum Periostin - High | -0.017 ± 0.088 | 0.147 ± 0.094 | 0.207 ± 0.092 | 0.185 ± 0.089 |
| Serum Periostin - Low | -0.040 ± 0.090 | 0.060 ± 0.093 | -0.013 ± 0.093 | 0.064 ± 0.089 |
| Current Post-BD FEV1 Reversibility - Yes | -0.081 ± 0.075 | 0.052 ± 0.077 | 0.049 ± 0.077 | 0.066 ± 0.073 |
| Allergic | -0.047 ± 0.073 | 0.131 ± 0.081 | 0.084 ± 0.077 | 0.065 ± 0.076 |
| Non-Allergic | -0.037 ± 0.131 | 0.050 ± 0.123 | 0.148 ± 0.129 | 0.164 ± 0.123 |
Forced expiratory volume in 1 second and forced vital capacity measures taken after bronchodilator use were reported.
| Liter | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Change from Baseline in Post-BD FEV1 | -0.064 ± 0.352 | 0.117 ± 0.389 | 0.099 ± 0.449 | 0.128 ± 0.415 |
| Change from Baseline in Post-BD FVC | -0.092 ± 0.353 | 0.088 ± 0.439 | 0.092 ± 0.515 | 0.083 ± 0.435 |
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Overall symptom score is the average of scores of daytime severity, daytime frequency, and nighttime severity symptoms. The daytime frequency and severity items are scored from 0 to 4, where a higher score indicates greater frequency/severity and nighttime severity item is scored from 0 to 4 , where a higher score indicates greater severity. Overall symptom score ranges from 0 to 4, where lower score indicates better asthma symptom while, higher score indicates worse asthma symptom.
| Units on a scale | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Blood Eosinophil Count -Eosinophilic | -0.57 ± 0.07 | -0.62 ± 0.07 | -0.78 ± 0.07 | -0.72 ± 0.07 |
| Blood Eosinophil Count -Non-Eosinophilic | -0.49 ± 0.08 | -0.60 ± 0.08 | -0.56 ± 0.08 | -0.72 ± 0.08 |
| Th2 Status - High | -0.54 ± 0.07 | -0.65 ± 0.08 | -0.62 ± 0.08 | -0.75 ± 0.08 |
| Th2 Status - Low | -0.50 ± 0.08 | -0.57 ± 0.07 | -0.72 ± 0.08 | -0.71 ± 0.08 |
| FENO - High | -0.52 ± 0.08 | -0.68 ± 0.07 | -0.75 ± 0.08 | -0.72 ± 0.08 |
| FENO - Low | -0.54 ± 0.07 | -0.55 ± 0.07 | -0.59 ± 0.08 | -0.71 ± 0.07 |
| Serum Periostin - High | -0.48 ± 0.07 | -0.54 ± 0.08 | -0.84 ± 0.08 | -0.74 ± 0.08 |
| Serum Periostin - Low | -0.58 ± 0.07 | -0.63 ± 0.07 | -0.47 ± 0.08 | -0.69 ± 0.07 |
| Current Post-BD FEV1 Reversibility - Yes | -0.55 ± 0.05 | -0.60 ± 0.06 | -0.64 ± 0.06 | -0.71 ± 0.06 |
| Allergic | -0.53 ± 0.07 | -0.59 ± 0.07 | -0.63 ± 0.07 | -0.67 ± 0.07 |
| Non-Allergic | -0.50 ± 0.09 | -0.60 ± 0.08 | -0.72 ± 0.09 | -0.85 ± 0.08 |
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Symptom score values for night time assessment is 0 (no asthma symptom) to 3 (unable to sleep because of asthma) and symptom score values for day time assessment is 0 (no asthma symptom) to 3 (unable to do normal activities due to asthma). Total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom.
| Units on a scale | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Daytime Severity | -0.483 ± 0.700 | -0.657 ± 0.726 | -0.669 ± 0.640 | -0.680 ± 0.688 |
| Daytime Frequency | -0.493 ± 0.792 | -0.598 ± 0.837 | -0.727 ± 0.753 | -0.754 ± 0.752 |
| Nighttime Severity | -0.643 ± 0.799 | -0.616 ± 0.687 | -0.807 ± 0.699 | -0.662 ± 0.730 |
The ACQ is a patient-reported questionnaire assessing asthma symptoms (ie, night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use and FEV1. The ACQ-6 is a shortened version of the ACQ that omits the FEV1 measurement from the original ACQ score. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).
| Units on a scale | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52 | -0.89 ± 0.91 | -1.24 ± 0.94 | -1.17 ± 1.00 | -1.19 ± 1.00 |
A severe asthma exacerbation is defined as an event that resulted in hospitalization. The severe AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
| events per person-year | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Rate of Severe Asthma Exacerbation Through Week 52 | 0.14 (0.08 to 0.22) | 0.04 (0.01 to 0.09) | 0.02 (0.00 to 0.07) | 0.03 (0.01 to 0.08) |
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first asthma exacerbation was reported.
| Days | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Time to First Asthma Exacerbation Through Week 52 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first severe asthma exacerbations (hospitalization) were reported.
| Days | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Time to First Severe Asthma Exacerbation Through Week 52 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
| Participants | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Number of Participants With at Least One Asthma Exacerbations Through Week 52 | 43 | 30 | 21 | 25 |
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Participants with severe asthma exacerbations (hospitalization) were reported.
| Participants | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52 | 9 | 5 | 3 | 4 |
The AQLQ(S) +12 is a 32-item questionnaire that measures the health-related quality of life experienced by asthma participants. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli) scaled on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment).
| Units on a scale | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52 | 1.04 ± 1.11 | 1.19 ± 0.90 | 0.93 ± 1.03 | 1.13 ± 1.13 |
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a visual analogue scale (VAS) that ranged from 0 to 100, where 0 indicated the worst health you can imagine and 100 indicated the best health you can imagine.
| Units on a scale | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Health State Valuation | 0.1051 ± 0.1511 | 0.0752 ± 0.2179 | 0.0729 ± 0.1624 | 0.0395 ± 0.1935 |
| Visual Analog Scale | 13.8 ± 17.6 | 14.0 ± 16.4 | 12.0 ± 18.0 | 12.3 ± 18.0 |
The total amount of study drug exposure (in milligram) for the entire study period was summarized.
| Milligram | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|
| Total Amount of Study Drug Exposure | 877.0 ± 116.9 | 2493.9 ± 640.4 | 6574.9 ± 1630.2 |
An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product. Serious adverse event is any adverse event that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period until and including the follow-up period (Week 64).
| Participants | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| TEAEs | 91 | 93 | 90 | 89 |
| TESAEs | 18 | 17 | 13 | 18 |
Adverse events observed in participants with clinically significant vital signs abnormalities were assessed.
| Participants | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Blood pressure diastolic increased | 0 | 1 | 0 | 0 |
| Blood pressure increased | 1 | 2 | 1 | 0 |
| Heart rate increased | 0 | 0 | 0 | 1 |
| Hypertension | 7 | 7 | 5 | 6 |
| Hypertensive crisis | 0 | 0 | 0 | 1 |
| Hypotension | 0 | 0 | 0 | 2 |
| Pyrexia | 0 | 2 | 2 | 0 |
| Respiratory rate increased | 0 | 0 | 0 | 1 |
An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations of blood and urine samples were performed.
| Participants | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Anaemia | 0 | 0 | 0 | 1 |
| Leukopenia | 0 | 1 | 0 | 0 |
| Lymphopenia | 0 | 1 | 0 | 0 |
| Neutropenia | 0 | 1 | 0 | 0 |
| Thrombocytopenia | 0 | 1 | 0 | 0 |
| Dyslipidaemia | 0 | 1 | 0 | 0 |
| Hepatic enzyme increased | 0 | 0 | 1 | 0 |
| Hypercholesterolaemia | 0 | 0 | 1 | 0 |
| Hyperuricaemia | 0 | 0 | 1 | 0 |
| Hypokalaemia | 0 | 0 | 1 | 0 |
| Vitamin D deficiency | 0 | 0 | 1 | 0 |
| Hematuria | 1 | 0 | 1 | 0 |
Adverse events observed in participants with clinically significant electrocardiogram abnormalities were assessed.
| Participants | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| Atrial fibrillation | 1 | 0 | 2 | 0 |
| Atrial flutter | 0 | 1 | 0 | 0 |
| Bundle branch block left | 0 | 0 | 1 | 0 |
| Supraventricular extrasystoles | 1 | 0 | 0 | 0 |
| Tachycardia | 1 | 1 | 1 | 2 |
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
| ng/mL | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|
| Week 4 | 3933.6 ± 3022.7 | 10733.1 ± 4649.4 | 39722.7 ± 15140.7 |
| Week 12 | 6215.8 ± 3779.2 | 16625.4 ± 7751.6 | 63223.7 ± 60627.6 |
| Week 20 | 6028.3 ± 2897.9 | 18237.1 ± 8721.9 | 64442.9 ± 22558.3 |
| Week 28 | 6084.1 ± 2885.5 | 19373.4 ± 9191.4 | 64659.9 ± 24121.6 |
| Week 40 | 6050.4 ± 3296.4 | 18926.1 ± 10252.7 | 64404.0 ± 26473.0 |
| Week 52 | 6027.2 ± 3024.8 | 18821.9 ± 10435.2 | 68899.1 ± 71137.2 |
| Week 64 | 632.8 ± 519.5 | 1991.2 ± 1882.4 | 6986.0 ± 5289.0 |
Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The number of participants with positive serum antibodies to MEDI9929 were presented.
| Participants | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| ADA Positive at Baseline | 7 | 1 | 2 | 2 |
| ADA prevalence | 13 | 6 | 2 | 4 |
| ADA incidence | 13 | 5 | 1 | 3 |
| Neutralizing antibody- ADA Positive | 0 | 0 | 0 | 0 |
Collected over From Day 1 upto Week 64. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/138 (0%) | 18/138 (13%) | 56/138 (40.6%) |
| MEDI9929 70 mg | 1/138 (0.7%) | 17/138 (12.3%) | 49/138 (35.5%) |
| MEDI9929 210 mg | 0/137 (0%) | 13/137 (9.5%) | 44/137 (32.1%) |
| MEDI9929 280 mg | 0/137 (0%) | 18/137 (13.1%) | 50/137 (36.5%) |
| Event | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 10/138 | 5/138 | 4/137 | 6/137 |
| PneumoniaInfections and infestations | 1/138 | 3/138 | 0/137 | 2/137 |
| Cardiac failureCardiac disorders | 1/138 | 0/138 | 1/137 | 0/137 |
| Hiatus herniaGastrointestinal disorders | 0/138 | 0/138 | 0/137 | 1/137 |
| Large intestine polypGastrointestinal disorders | 0/138 | 0/138 | 0/137 | 1/137 |
| Pancreatitis acuteGastrointestinal disorders | 0/138 | 0/138 | 0/137 | 1/137 |
| Non-cardiac chest painGeneral disorders | 1/138 | 0/138 | 1/137 | 0/137 |
| CholelithiasisHepatobiliary disorders | 0/138 | 0/138 | 0/137 | 1/137 |
| Anaphylactic shockImmune system disorders | 0/138 | 0/138 | 0/137 | 1/137 |
| ErysipelasInfections and infestations | 0/138 | 0/138 | 0/137 | 1/137 |
| Event | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 47/138 | 31/138 | 23/137 | 35/137 |
| NasopharyngitisInfections and infestations | 16/138 | 19/138 | 19/137 | 15/137 |
| HeadacheNervous system disorders | 6/138 | 6/138 | 11/137 | 5/137 |
| BronchitisInfections and infestations | 7/138 | 7/138 | 5/137 | 9/137 |
The intent-to-treat population included participants who are randomized and received any study drug.
| Age, Continuous(Years) | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg | Total |
|---|---|---|---|---|---|
| Mean | 52.32 ± 11.71 | 50.80 ± 12.36 | 52.66 ± 12.67 | 50.43 ± 12.25 | 51.55 ± 12.25 |
| Sex: Female, Male(Participants) | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg | Total |
|---|---|---|---|---|---|
| Female | 94 | 89 | 87 | 91 | 361 |
| Male | 44 | 49 | 50 | 46 | 189 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 2 | 4 |
| Not Hispanic or Latino | 137 | 138 | 136 | 135 | 546 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | MEDI9929 70 mg | MEDI9929 210 mg | MEDI9929 280 mg | Total |
|---|---|---|---|---|---|
| Asian | 6 | 3 | 5 | 5 | 19 |
| Black or African American | 6 | 4 | 3 | 6 | 19 |
| White | 123 | 131 | 128 | 122 | 504 |
| Other | 2 | 0 | 0 | 2 | 4 |
| Multiple Categories Checked | 1 | 0 | 1 | 2 | 4 |
Showing the first 100 of 107 sites across 12 countries. Choose a country and city above to see the rest.
Ran from Dec 2013 to primary completion in Dec 2016, 35 months.
Results were first posted in Dec 2018, 1 year 11 months after primary completion.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 35 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab